The beneficial value of 18F FDG PET/CT in the follow-up of stage III non-small cell lung cancer patients
- Conditions
- Lung cancerLung carcinoma1002765610029107
- Registration Number
- NL-OMON56590
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 690
• Cytological or histologically proven stage III non-small cell lung cancer
before start of curative intent treatment
• Treated with curative intent and started follow-up care
• All adjuvant treatments are permitted as co-intervention during follow-up care
• Age 18 years or older
• ECOG Performance Status classification 0-2 at moment of inclusion
• Written and signed informed consent by the patient or their representative
(with the understanding that consent may be withdrawn by the patient or their
representative at any time without consequences to future medical care)
• Life expectancy shorter than 6 months at the end of curative intent treatment
• Evidence of recurrence after end of curative intent treatment and before
randomization (4 months follow-up)
• Any condition that, in the opinion of the investigator, would interfere with
evaluation of the intervention or interpretation of HRQOL or other study
results.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Overall survival (OS) will be defined as time from end of curative intent<br /><br>treatment until death or loss to follow-up or end of study defined as 3 years<br /><br>after end of curative treatment. OS will be recorded in the eCRF and<br /><br>cross-validated through a linkage with the National Cancer Registry. Primary<br /><br>analyses will be performed on an intention-to-treat basis. The secondary<br /><br>analyses will include per protocol analyses as well. </p><br>
- Secondary Outcome Measures
Name Time Method